IFCT-1502 CLINIVO: real-world evidence of long-term survival with nivolumab in a nationwide cohort of patients with advanced non-small-cell lung cancer

BACKGROUND: Immunotherapy using inhibitors targeting immune checkpoint programmed cell death protein 1 (PD-1)/programmed death-ligand 1 (PD-L1) is currently the standard of care in patients with advanced non-small-cell lung cancer (NSCLC). MATERIALS AND METHODS: We carried out a nationwide cohort re...

Descripción completa

Detalles Bibliográficos
Autores principales: Molinier, O., Besse, B., Barlesi, F., Audigier-Valette, C., Friard, S., Monnet, I., Jeannin, G., Mazières, J., Cadranel, J., Hureaux, J., Hilgers, W., Quoix, E., Coudert, B., Moro-Sibilot, D., Fauchon, E., Westeel, V., Brun, P., Langlais, A., Morin, F., Souquet, P.J., Girard, N.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2021
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8764511/
https://www.ncbi.nlm.nih.gov/pubmed/34953398
http://dx.doi.org/10.1016/j.esmoop.2021.100353

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8764511/
https://www.ncbi.nlm.nih.gov/pubmed/34953398
http://dx.doi.org/10.1016/j.esmoop.2021.100353

Ejemplares similares